Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Phase 1B, Pilot Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety, Activity of Pembrolizumab Administered Intra-lymphatically Using the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T- Cell Lymphoma (CTCL)
Sponsor: Sorrento Therapeutics, Inc.
This PHASE1 trial investigates Mycosis Fungoides and is currently ongoing. Sorrento Therapeutics, Inc. leads this study, which shows 10 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Nov 2024 — Present [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sorrento Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .